{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+ERA&page=2",
    "query": {
      "intervention": "oral ERA",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+ERA&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T03:56:10.382Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01698918",
      "title": "Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)",
          "type": "DRUG"
        },
        {
          "name": "Standard of care to treat stomatitis (Stomatitis sub-study)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 202,
      "start_date": "2013-03-07",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01698918"
    },
    {
      "nct_id": "NCT06218303",
      "title": "Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ductal Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "MUC1 Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiltonol®",
          "type": "DRUG"
        },
        {
          "name": "Aromatase Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Selective estrogen receptor modulator (SERM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Finn, Olivera, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2024-02-07",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06218303"
    },
    {
      "nct_id": "NCT06492616",
      "title": "A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Elacestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stemline Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4220,
      "start_date": "2024-09-27",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 176,
      "location_summary": "Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 139 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06492616"
    },
    {
      "nct_id": "NCT01273168",
      "title": "Endoxifen in Adults With Hormone Receptor Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hormone Receptor-Positive Breast",
        "Gynecologic",
        "Desmoid",
        "Hormone Receptor-Positive Neoplasms"
      ],
      "interventions": [
        {
          "name": "Z-Endoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-03-01",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273168"
    },
    {
      "nct_id": "NCT00832507",
      "title": "Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Cicletanine",
          "type": "DRUG"
        },
        {
          "name": "Cicletanine Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 162,
      "start_date": "2009-01",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-02-04",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 39,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00832507"
    },
    {
      "nct_id": "NCT07683325",
      "title": "NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrostenotic Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Ontunisertib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agomab Spain S.L.U.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2026-10-30",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 2,
      "location_summary": "Bradenton, Florida • Fort Worth, Texas",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07683325"
    },
    {
      "nct_id": "NCT06105632",
      "title": "A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07220060 CDK4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 333,
      "start_date": "2024-01-09",
      "completion_date": "2028-01-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 9,
      "location_summary": "Irvine, California • Los Angeles, California • Newport Beach, California + 3 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06105632"
    },
    {
      "nct_id": "NCT00265759",
      "title": "Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "exemestane",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 622,
      "start_date": "2006-01",
      "completion_date": "2019-11-27",
      "has_results": true,
      "last_update_posted_date": "2025-04-23",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Houston, Texas • Laredo, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Laredo",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00265759"
    },
    {
      "nct_id": "NCT00134680",
      "title": "Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2000-01",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2014-09-16",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134680"
    },
    {
      "nct_id": "NCT02271282",
      "title": "Estradiol-Receptor Blockade in Older Men and Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Toremifene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "GHRH/Ghrelin combined Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-12",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-09-14",
      "last_synced_at": "2026-09-24T03:56:10.382Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02271282"
    }
  ]
}